Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

Authors: Moreau, Philippe ^*, Hulin, Cyrille, Perrot, Aurore, Arnulf, Bertrand, Belhadj, Karim, Benboubker, Lotfi, Zweegman, Sonja, Caillon, Hélène, Caillot, Denis, Avet-Loiseau, Hervé, Delforge, Michel, Dejoie, Thomas, Facon, Thierry, Sonntag, Cécile, Fontan, Jean, Mohty, Mohamad, Jie, Kon-Siong, Karlin, Lionel, Kuhnowski, Frédérique, Lambert, Jérôme, Leleu, Xavier, Macro, Margaret, Orsini-Piocelle, Frédérique, Roussel, Murielle, Schiano de Colella, Jean Marc, van de Donk, Niels WCJ, Wuillème, Soraya, Broijl, Annemiek, Touzeau, Cyrille, Tiab, Mourad, Marolleau, Jean-Pierre, Meuleman, Nathalie, Vekemans, Marie-Christiane, Westerman, Matthijs, Klein, Saskia K, Levin, Mark-David, Offner, Fritz, Escoffre-Barbe, Martine, Eveillard, Jean-Richard, Garidi, Réda, Hua, Winnie, Wang, Jianping, Tuozzo, Alba, de Boer, Carla, Rowe, Melissa, Vanquickelberghe, Veronique, Carson, Robin, Vermeulen, Jessica, Corre, Jill, Sonneveld, Pieter

Source: In The Lancet Oncology August 2024 25(8):1003-1014

Characteristics, primary treatment, and survival of MDS/MPN with neutrophilia: a population-based study

Authors: Klein, Saskia K., Huls, Gerwin A., Visser, Otto, Kluin-Nelemans, Hanneke C., Dinmohamed, Avinash G.

Source: In Blood Advances 26 December 2023 7(24):7554-7563

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial

Authors: Groen, Kaz, Stege, Claudia A.M., Nasserinejad, Kazem, de Heer, Koen, van Kampen, Roel J.W., Leys, Rineke B.L., Thielen, Noortje, Westerman, Matthijs, Wu, Ka-Lung, Ludwig, Inge, Issa, Djamila E., Velders, Gerjo A., Vekemans, Marie-Christiane, Timmers, Gert-Jan, de Boer, Fransien, Tick, Lidwine W., Verbrugge, Annelies, Buitenhuis, Danny, Cunha, Sonia M., van der Spek, Ellen, de Waal, Esther G.M., Sohne, Maaike, Sonneveld, Pieter, Nijhof, Inger S., Klein, Saskia K., van de Donk, Niels W.C.J., Levin, Mark-David, Ypma, Paula F., Zweegman, Sonja

Source: In eClinicalMedicine September 2023 63

Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial

Authors: Veringa, Anette, Brüggemann, Roger J., Span, Lambert F.R., Biemond, Bart J., de Boer, Mark G.J., van den Heuvel, Edwin R., Klein, Saskia K., Kraemer, Doris, Minnema, Monique C., Prakken, Niek H.J., Rijnders, Bart J.A., Swen, Jesse J., Verweij, Paul E., Wondergem, Mariëlle J., Ypma, Paula F., Blijlevens, Nicole, Kosterink, Jos G.W., van der Werf, Tjip S., Alffenaar, Jan-Willem C.

Source: In International Journal of Antimicrobial Agents February 2023 61(2)

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma

Authors: Frerichs, Kristine A. ¹, Minnema, Monique C. ², Levin, Mark-David ³, Broijl, Annemiek ⁴, Bos, Gerard M.J. ⁵, Kersten, Marie José ⁶, Mutis, Tuna ¹, Verkleij, Christie P.M. ¹, Nijhof, Inger S. ¹, Maas-Bosman, Patricia W.C. ¹, Klein, Saskia K. ^{7, 8}, Zweegman, Sonja ¹, Sonneveld, Pieter ⁴, van de Donk, Niels W.C.J. ^{1, *}

Source: In Blood Advances 14 December 2021 5(23):5128-5139

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

Authors: Moreau, Philippe ^*, Hulin, Cyrille, Perrot, Aurore, Arnulf, Bertrand, Belhadj, Karim, Benboubker, Lotfi, Béné, Marie C, Zweegman, Sonja, Caillon, Hélène, Caillot, Denis, Corre, Jill, Delforge, Michel, Dejoie, Thomas, Doyen, Chantal, Facon, Thierry, Sonntag, Cécile, Fontan, Jean, Mohty, Mohamad, Jie, Kon-Siong, Karlin, Lionel, Kuhnowski, Frédérique, Lambert, Jérôme, Leleu, Xavier, Macro, Margaret, Orsini-Piocelle, Frédérique, Roussel, Murielle, Stoppa, Anne-Marie, van de Donk, Niels W C J, Wuillème, Soraya, Broijl, Annemiek, Touzeau, Cyrille, Tiab, Mourad, Marolleau, Jean-Pierre, Meuleman, Nathalie, Vekemans, Marie-Christiane, Westerman, Matthijs, Klein, Saskia K, Levin, Mark-David, Offner, Fritz, Escoffre-Barbe, Martine, Eveillard, Jean-Richard, Garidi, Réda, Ahmadi, Tahamtan, Krevvata, Maria, Zhang, Ke, de Boer, Carla, Vara, Sanjay, Kampfenkel, Tobias, Vanquickelberghe, Veronique, Vermeulen, Jessica, Avet-Loiseau, Hervé, Sonneveld, Pieter

Source: In The Lancet Oncology October 2021 22(10):1378-1390

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Authors: Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, Gradowska, Patrycja, Biemond, Bart J., Spertini, Olivier, Vellenga, Edo, Griskevicius, Laimonas, Tick, Lidwine W., Jongen-Lavrencic, Mojca, van Marwijk Kooy, Marinus, Vekemans, Marie-Christiane, van der Velden, Walter J.F.M., Beverloo, Berna, Michaux, Lucienne, Graux, Carlos, Deeren, Dries, de Weerdt, Okke, van Esser, Joost W.J., Bargetzi, Mario, Klein, Saskia K., Gadisseur, Alain, Westerweel, Peter E., Veelken, Hendrik, Gregor, Michael, Silzle, Tobias, van Lammeren-Venema, Daniëlle, Moors, Ine, Breems, Dimitri A., Hoogendoorn, Mels, Legdeur, Marie-Cecile J.C., Fischer, Thomas, Kuball, Juergen, Cornelissen, Jan, Porkka, Kimmo, Juliusson, Gunnar, Meyer, Peter, Höglund, Martin, Gjertsen, Bjorn T., Janssen, Jeroen J.W.M., Huls, Gerwin, Passweg, Jakob, Cloos, Jacqueline, Valk, Peter J.M., van Elssen, Catharina H.M.J., Manz, Markus G., Floisand, Yngvar, Ossenkoppele, Gert J.

Source: In Blood Advances 23 February 2021 5(4):1110-1121

Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.

Authors: Huls, Gerwin, Chitu, Dana A., Tick, Lidwine, Boersma, Rinske, Breems, Dimitri, Herbers, Alexandra, Klein, Saskia K., de Jonge, Suzan, Westerweel, Peter E., Cruijsen, Marjan, Hoogendoorn, Mels, Cuijpers, Marlous, Deeren, Dries, Bailly, Benjamin, Visser, Otto, van Rhenen, Anna, Posthuma, Eduard F. M., Valk, Peter J. M., Cloos, Jacqueline, Ammatuna, Emanuele

Source: Annals of Hematology; Jan2025, Vol. 104 Issue 1, p361-368, 8p

Subject Terms: ACUTE myeloid leukemia, DECITABINE, CANCER chemotherapy, PROTEIN-tyrosine kinase inhibitors, MYELODYSPLASTIC syndromes

Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial

Authors: Roussel, Murielle, Moreau, Philippe, Hebraud, Benjamin, Laribi, Kamel, Jaccard, Arnaud, Dib, Mamoun, Slama, Borhane, Dorvaux, Véronique, Royer, Bruno, Frenzel, Laurent, Zweegman, Sonja, Klein, Saskia K, Broijl, Annemiek, Jie, Kon-Siong, Wang, Jianping, Vanquickelberghe, Veronique, de Boer, Carla, Kampfenkel, Tobias, Gries, Katharine S, Fastenau, John, Sonneveld, Pieter ^*

Source: In The Lancet Haematology December 2020 7(12):e874-e883

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Authors: Huls, Gerwin ^*, Chitu, Dana A., Pabst, Thomas, Klein, Saskia K., Stussi, Georg, Griskevicius, Laimonas, Valk, Peter J.M., Cloos, Jacqueline, van de Loosdrecht, Arjan A., Breems, Dimitri, van Lammeren-Venema, Danielle, van Zeventer, Isabelle, Boersma, Rinske, Jongen-Lavrencic, Mojca, Fehr, Martin, Hoogendoorn, Mels, Manz, Markus G., Söhne, Maaike, van Marwijk Kooy, Rien, Deeren, Dries, van der Poel, Marjolein W.M., Legdeur, Marie Cecile, Tick, Lidwine, Chalandon, Yves, Ammatuna, Emanuele, Blum, Sabine, Löwenberg, Bob, Ossenkoppele, Gert J.

Source: In Blood Advances 22 September 2020 4(18):4267-4277

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Authors: Moreau, Philippe, Attal, Michel, Hulin, Cyrille, Arnulf, Bertrand, Belhadj, Karim, Benboubker, Lotfi, Béné, Marie C, Broijl, Annemiek, Caillon, Hélène, Caillot, Denis, Corre, Jill, Delforge, Michel, Dejoie, Thomas, Doyen, Chantal, Facon, Thierry, Sonntag, Cécile, Fontan, Jean, Garderet, Laurent, Jie, Kon-Siong, Karlin, Lionel, Kuhnowski, Frédérique, Lambert, Jérôme, Leleu, Xavier, Lenain, Pascal, Macro, Margaret, Mathiot, Claire, Orsini-Piocelle, Frédérique, Perrot, Aurore, Stoppa, Anne-Marie, van de Donk, Niels WCJ, Wuilleme, Soraya, Zweegman, Sonja, Kolb, Brigitte, Touzeau, Cyrille, Roussel, Murielle, Tiab, Mourad, Marolleau, Jean-Pierre, Meuleman, Nathalie, Vekemans, Marie-Christiane, Westerman, Matthijs, Klein, Saskia K, Levin, Mark-David, Fermand, Jean Paul, Escoffre-Barbe, Martine, Eveillard, Jean-Richard, Garidi, Reda, Ahmadi, Tahamtan, Zhuang, Sen, Chiu, Christopher, Pei, Lixia, de Boer, Carla, Smith, Elena, Deraedt, William, Kampfenkel, Tobias, Schecter, Jordan, Vermeulen, Jessica, Avet-Loiseau, Hervé, Sonneveld, Pieter

Source: In The Lancet 6-12 July 2019 394(10192):29-38

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial

Authors: van de Donk, Niels WCJ, van der Holt, Bronno, Minnema, Monique C, Vellenga, Edo, Croockewit, Sandra, Kersten, Marie José, von dem Borne, Peter A, Ypma, Paula, Schaafsma, Ron, de Weerdt, Okke, Klein, Saskia K, Delforge, Michel, Levin, Mark-David, Bos, Gerard M, Jie, Kon-Siong G, Sinnige, Harm, Coenen, Jules LLM, de Waal, Esther G, Zweegman, Sonja, Sonneveld, Pieter, Lokhorst, Henk M

Source: In The Lancet Haematology October 2018 5(10):e479-e492

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes.

Authors: Groen, Kazimierz, Smits, Febe, Nasserinejad, Kazem, Levin, Mark‐David, Regelink, Josien C., Timmers, Gert‐Jan, de Waal, Esther G. M., Westerman, Matthijs, Velders, Gerjo A., de Heer, Koen, Leys, Rineke B. L., van Kampen, Roel J. W., Stege, Claudia A. M., Seefat, Maarten R., Nijhof, Inger S., van der Spek, Ellen, Klein, Saskia K., van de Donk, Niels W. C. J., Ypma, Paula F., Zweegman, Sonja

Source: HemaSphere; Jul2024, Vol. 8 Issue 7, p1-5, 5p

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Authors: Nijhof, Inger S., Franssen, Laurens E., Levin, Mark-David, Bos, Gerard M.J., Broijl, Annemiek, Klein, Saskia K., Koene, Harry R., Bloem, Andries C., Beeker, Aart, Faber, Laura M., van der Spek, Ellen, Ypma, Paula F., Raymakers, Reinier, van Spronsen, Dick-Johan, Westerweel, Peter E., Oostvogels, Rimke, van Velzen, Jeroen, van Kessel, Berris, Mutis, Tuna, Sonneveld, Pieter, Zweegman, Sonja, Lokhorst, Henk M., van de Donk, Niels W.C.J.

Source: In Blood 10 November 2016 128(19):2297-2306

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

Authors: Zweegman, Sonja ^*, van der Holt, Bronno, Mellqvist, Ulf-Henrik, Salomo, Morten, Bos, Gerard M.J., Levin, Mark-David, Visser-Wisselaar, Heleen, Hansson, Markus, van der Velden, Annette W.G., Deenik, Wendy, Gruber, Astrid, Coenen, Juleon L.L.M., Plesner, Torben, Klein, Saskia K., Tanis, Bea C., Szatkowski, Damian L., Brouwer, Rolf E., Westerman, Matthijs, Leys, M.(Rineke) B.L., Sinnige, Harm A.M., Haukås, Einar, van der Hem, Klaas G., Durian, Marc F., Mattijssen, E.(Vera)J.M., van de Donk, Niels W.C.J., Stevens-Kroef, Marian J.P.L., Sonneveld, Pieter, Waage, Anders

Source: In Blood 3 March 2016 127(9):1109-1116

MM-491 Daratumumab (DARA) + Bortezomib/Thalidomide/Dexamethasone (D-VTd) Followed by DARA Maintenance in Transplant-eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): >6-Year Update of the Phase 3 CASSIOPEIA Study

Authors: Moreau, Philippe, Hulin, Cyrille, Perrot, Aurore, Arnulf, Bertrand, Belhadj, Karim, Benboubker, Lotfi, Zweegman, Sonja, Caillon, Hélène, Caillot, Denis, Avet-Loiseau, Hervé, Delforge, Michel, Dejoie, Thomas, Facon, Thierry, Sonntag, Cécile, Fontan, Jean, Mohty, Mohamad, Siong Jie, Kon-Siong, Karlin, Lionel, Kuhnowski, Frédérique, Lambert, Jérôme, Leleu, Xavier, Macro, Margaret, Orsini-Piocelle, Frédérique, Roussel, Murielle, van de Donk, Niels W.C.J., Wuillème, Soraya, Broijl, Annemiek, Tiab, Mourad, Fontan, Jean-Pierre, Meuleman, Nathalie, Vekemans, Marie-Christiane, Westerman, Matthijs, Klein, Saskia K., Levin, Mark-David, Offner, Fritz, Escoffre-Barbe, Martine, Fontan, Jean-Richard, Garidi, Réda, Hua, Winnie, Wang, Jianping, Tuozzo, Alba, de Boer, Carla J., Rowe, Melissa, Vanquickelberghe, Veronique, Carson, Robin, Vermeulen, Jessica, Corre, Jill, Sonneveld, Pieter

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S560-S561

Daratumumab (DARA) + Bortezomib/Thalidomide/Dexamethasone (D-VTd) Followed by DARA Maintenance in Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): >6-Year Update of the Phase 3 CASSIOPEIA Study

Authors: Moreau, Philippe, Hulin, Cyrille, Perrot, Aurore, Arnulf, Bertrand, Belhadj, Karim, Benboubker, Lotfi, Zweegman, Sonja, Caillon, Hélène, Caillot, Denis, Avet-Loiseau, Hervé, Delforge, Michel, Dejoie, Thomas, Facon, Thierry, Sonntag, Cécile, Fontan, Jean, Mohty, Mohamad, Jie, Kon-Siong, Karlin, Lionel, Kuhnowski, Frédérique, Lambert, Jérôme, Leleu, Xavier, Macro, Margaret, Orsini-Piocelle, Frédérique, Roussel, Murielle, Marc Schiano de Colella, Jean, van de Donk, Niels W.C.J., Wuillème, Soraya, Broijl, Annemiek, Touzeau, Cyrille, Tiab, Mourad, Marolleau, Jean-Pierre, Meuleman, Nathalie, Vekemans, Marie-Christiane, Westerman, Matthijs, Klein, Saskia K., Levin, Mark-David, Offner, Fritz, Escoffre-Barbe, Martine, Eveillard, Jean-Richard, Garidi, Réda, Hua, Winnie, Wang, Jianping, Tuozzo, Alba, de Boer, Carla J., Rowe, Melissa, Vanquickelberghe, Veronique, Carson, Robin, Vermeulen, Jessica, Corre, Jill, Sonneveld, Pieter

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S240-S240

Clinical Impact of Polymerase Chain Reaction–Based Aspergillus and Azole Resistance Detection in Invasive Aspergillosis: A Prospective Multicenter Study.

Authors: Huygens, Sammy, Dunbar, Albert, Buil, Jochem B, Klaassen, Corné H W, Verweij, Paul E, Dijk, Karin van, Jonge, Nick de, Janssen, Jeroen J W M, Velden, Walter J F M van der, Biemond, Bart J, Bart, Aldert, Bruns, Anke H W, Haas, Pieter-Jan A, Demandt, Astrid M P, Oudhuis, Guy, von dem Borne, Peter, Beek, Martha T van der, Klein, Saskia K, Godschalk, Peggy, Span, Lambert F R

Source: Clinical Infectious Diseases; Jul2023, Vol. 77 Issue 1, p38-45, 8p

Subject Terms: RESEARCH, GENETIC mutation, CONFIDENCE intervals, MANN Whitney U Test, PULMONARY aspergillosis, PEARSON correlation (Statistics), DESCRIPTIVE statistics, CHI-squared test, POLYMERASE chain reaction, DRUG resistance in microorganisms, BIOLOGICAL assay, DATA analysis software, COMPUTED tomography, LONGITUDINAL method

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.

Authors: Hilberink, Jacobien R., van Zeventer, Isabelle A., Chitu, Dana A., Pabst, Thomas, Klein, Saskia K., Stussi, Georg, Griskevicius, Laimonas, Valk, Peter J. M., Cloos, Jacqueline, van de Loosdrecht, Arjan A., Breems, Dimitri, van Lammeren-Venema, Danielle, Boersma, Rinske, Jongen-Lavrencic, Mojca, Fehr, Martin, Hoogendoorn, Mels, Manz, Markus G., Söhne, Maaike, van Marwijk Kooy, Rien, Deeren, Dries

Source: Blood Cancer Journal; 6/19/2023, Vol. 13 Issue 1, p1-9, 9p

Subject Terms: OLDER patients, GENETIC profile, DECITABINE, ACUTE myeloid leukemia, PHYSICAL mobility

Cryoglobulinemic Vasculitis in Disguise: Cryofibrinogenemia as Variant of Monoclonal Gammopathy of Renal Significance

Authors: Gant, Christina M., Koelman, Carin A., Nguyen, Tri Q., Abrahams, Alferso C., Wetzels, Jack F.M., Duineveld, Caroline, Jak, Margot, Minnema, Monique C., Klein, Saskia K., Jacobs, Joannes F.M., Bosma, Renate J.

Source: In American Journal of Kidney Diseases March 2024 83(3):415-419